Against empirical metformin use in the obese gravida at early pregnancy: A critical appraisal

Dimitrios G. Goulis,
Professor in Reproductive Endocrinology, Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, GreeceObesity in pregnancy confers substantial maternal and fetal risks, including gestational diabetes mellitus (GDM), hypertensive disorders, macrosomia, and adverse neonatal outcomes. The pharmacological potential of metformin, an insulin sensitizer with a well-established safety record in type 2 diabetes mellitus and polycystic ovary syndrome (PCOS), has prompted increasing interest in its prophylactic use in obese pregnant women. However, current evidence does not support its routine antenatal prescription in this population, and several mechanistic, clinical, and ethical concerns warrant critical scrutiny.The landmark EMPOWaR and MOP trials, both double-blind, placebo-controlled randomized studies, demonstrated no statistically significant reduction in primary outcomes, including large-for-gestational-age (LGA) neonates, GDM incidence, gestational weight gain, or composite adverse perinatal outcomes, in obese women receiving metformin from the first trimester. Despite the well-documented transplacental passage of metformin, the implications of fetal exposure remain incompletely characterized across gestation. Notably, metformin-exposed offspring in some cohorts have demonstrated paradoxical increases in childhood adiposity at follow-up assessments, raising concerns about long-term metabolic programming, a finding with considerable epigenetic plausibility, given metformin’s AMPK-mediated interference with mitochondrial function during critical developmental windows.From a pharmacokinetic standpoint, renal clearance of metformin increases substantially during pregnancy due to augmented glomerular filtration, rendering standard dosing regimens potentially subtherapeutic; in contrast, dose escalation introduces gastrointestinal intolerability and a theoretical risk of lactic acidosis in patients with pregnancy-associated physiological hemodynamic shifts. Furthermore, conflating insulin resistance in obesity with established GDM pathophysiology oversimplifies the metabolic heterogeneity of the obese gravid state, in which inflammatory dysregulation, adipokine imbalance, and placental dysfunction contribute independently to adverse outcomes beyond hyperglycemia alone.
Ethical considerations also merit emphasis: Obese pregnant women without confirmed glucose dysregulation or polycystic ovary syndrome represent a population for whom informed consent regarding off-label use, unresolved fetal safety data, and the absence of regulatory approval for this indication must be transparently communicated.
In conclusion, although metformin’s therapeutic role in confirmed GDM and insulin-resistant states remains validated, its empirical prescription in normoglycemic obese pregnant women at early gestation is premature, insufficiently evidence-based, and potentially carries risk to the developing conceptus.